Kyntra Bio, Inc. (KYNB)
4.51
-0.14
(-3.01%)
USD |
NASDAQ |
Oct 30, 16:00
4.51
0.00 (0.00%)
After-Hours: 16:46
Kyntra Bio Enterprise Value : -50.49M for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | -50.49M |
| October 28, 2026 | -50.21M |
| October 27, 2026 | -51.10M |
| October 26, 2026 | -51.10M |
| October 23, 2026 | -50.77M |
| October 22, 2026 | -48.18M |
| October 21, 2026 | -48.22M |
| October 20, 2026 | -47.94M |
| October 19, 2026 | -47.94M |
| October 16, 2026 | -49.68M |
| October 15, 2026 | -47.61M |
| October 14, 2026 | -46.78M |
| October 13, 2026 | -45.55M |
| October 12, 2026 | -44.54M |
| October 09, 2026 | -44.58M |
| October 08, 2026 | -45.19M |
| October 07, 2026 | -44.50M |
| October 06, 2026 | -45.19M |
| October 05, 2026 | -44.66M |
| October 02, 2026 | -43.77M |
| October 01, 2026 | -43.00M |
| September 30, 2026 | -42.39M |
| September 29, 2026 | -41.82M |
| September 28, 2026 | -41.38M |
| September 25, 2026 | -41.22M |
| Date | Value |
|---|---|
| September 24, 2026 | -40.97M |
| September 23, 2026 | -39.96M |
| September 22, 2026 | -39.84M |
| September 21, 2026 | -40.16M |
| September 18, 2026 | -40.67M |
| September 17, 2026 | -40.57M |
| September 16, 2026 | -38.50M |
| September 15, 2026 | -37.86M |
| September 14, 2026 | -36.80M |
| September 11, 2026 | -37.05M |
| September 10, 2026 | -37.03M |
| September 09, 2026 | -36.76M |
| September 08, 2026 | -36.03M |
| September 04, 2026 | -34.70M |
| September 03, 2026 | -34.94M |
| September 02, 2026 | -34.78M |
| September 01, 2026 | -37.13M |
| August 31, 2026 | -37.82M |
| August 28, 2026 | -36.84M |
| August 27, 2026 | -36.93M |
| August 26, 2026 | -36.50M |
| August 25, 2026 | -36.52M |
| August 24, 2026 | -37.01M |
| August 21, 2026 | -38.87M |
| August 20, 2026 | -39.68M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vericel Corp. | 2.128B |
| Nektar Therapeutics | 788.79M |
| Capricor Therapeutics, Inc. | 238.37M |
| ARS Pharmaceuticals, Inc. | 316.77M |
| ACADIA Pharmaceuticals, Inc. | 2.691B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 11.97M |
| Revenue (Quarterly) | -1.474M |
| Total Expenses (Quarterly) | -13.45M |
| EPS Diluted (Quarterly) | 2.958 |
| Profit Margin (Quarterly) | -812.3% |
| Earnings Yield | 716.3% |
| Normalized Earnings Yield | 741.84 |